Climb Bio director files to sell $1.46M stock

Climb Bio, Inc. (CLYM) has a director, Stephen Thomas, filing a notice under Rule 144 to potentially sell up to 100,000 shares of common stock.

Available on EDGAR 09/15/2026 - 04:27 PM EDT Accepted by SEC EDGAR 09/15/2026 - 04:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Climb Bio, Inc. (CLYM) has a director, Stephen Thomas, filing a notice under Rule 144 to potentially sell up to 100,000 shares of common stock. The shares relate to Performance Stock Units acquired from the issuer on August 7, 2025. As of September 15, 2026, 57,436,255 shares of common stock were outstanding and listed on NASDAQ.

Key Figures

Shares to be sold: 100,000 shares Aggregate market value of shares: $1,456,000.00 Shares outstanding: 57,436,255 shares +2 more

5 metrics

Shares to be sold 100,000 shares Maximum number of Climb Bio, Inc. common shares covered by the Rule 144 notice

Aggregate market value of shares $1,456,000.00 Reported value for the 100,000 common shares in the Rule 144 filing

Shares outstanding 57,436,255 shares Climb Bio, Inc. common stock outstanding as of September 15, 2026

Planned sale date reference September 15, 2026 Date associated with the securities information for the planned Rule 144 sale

Award acquisition date August 7, 2025 Date Performance Stock Units were acquired from the issuer that relate to the 100,000 shares

Key Terms

Rule 144, Performance Stock Units, aggregate market value, Securities To Be Sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Performance Stock Units financial

"Common | 08/07/2025 | Performance Stock Units | Issuer"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 100000 | 1456000.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Securities To Be Sold regulatory

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for CLYM?

The filing discloses that director Stephen Thomas has filed a Rule 144 notice for the potential sale of up to 100,000 shares of Climb Bio, Inc. common stock, which are tied to Performance Stock Units acquired from the issuer on August 7, 2025.

How many CLYM shares are covered by Stephen Thomas’s Rule 144 notice?

The notice covers up to 100,000 shares of Climb Bio, Inc. common stock. These shares are associated with Performance Stock Units acquired from the issuer on August 7, 2025.

What is the aggregate market value of the CLYM shares in this Form 144?

The Form 144 reports an aggregate market value of $1,456,000.00 for the 100,000 shares of Climb Bio, Inc. common stock covered by the notice, based on market information at the time of the filing.

How many CLYM shares were outstanding as of the date referenced in the notice?

The notice states that 57,436,255 shares of Climb Bio, Inc. common stock were outstanding as of September 15, 2026, with the shares listed on NASDAQ.

Through which broker are the CLYM shares in this Rule 144 notice planned to be sold?

The potential sale of Climb Bio, Inc. shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What type of equity award is linked to the CLYM shares in the Form 144?

The shares in the notice are linked to Performance Stock Units acquired from Climb Bio, Inc. on August 7, 2025, which are indicated as the source of the 100,000 shares to be potentially sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002027962
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CLIMB BIO, INC.
SEC File Number	001-40708
Address of Issuer	20 William Street Wellesley Hills MASSACHUSETTS 02481
Phone	866-857-2596
Name of Person for Whose Account the Securities are To Be Sold	STEPHEN THOMAS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	1456000.00	57436255	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/07/2025	Performance Stock Units	Issuer			100000	08/07/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Stephen Thomas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)